본문으로 건너뛰기
← 뒤로

Identification of Drug-resistant Cell Subpopulations in Colorectal Cancer Through Single-cell Analysis and Exploration of Potential Therapeutic Strategies.

2/5 보강
Current medicinal chemistry 📖 저널 OA 2.3% 2021: 0/1 OA 2023: 0/1 OA 2024: 0/1 OA 2025: 0/28 OA 2026: 2/55 OA 2021~2026 2026 Single-cell and spatial transcriptom
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-30

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
state transitions, forming two distinct branches
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[DISCUSSION] We identified an oxaliplatin-resistant subpopulation of Epithelial Cells (EpC2) in CRC, elucidated its multi-layered resistance mechanisms, and integrated multi- omics and cMAP database analyses to predict a potential intervention drug. [CONCLUSION] This study provided potential therapeutic possibilities for oxaliplatin resistance, contributing to CRC treatment.
OpenAlex 토픽 · Single-cell and spatial transcriptomics Bioinformatics and Genomic Networks Ferroptosis and cancer prognosis

Chen Y, Wang D

📝 환자 설명용 한 줄

[INTRODUCTION] The therapeutic efficacy of Colorectal Cancer (CRC) is often compromised by resistance to the standard chemotherapy agent oxaliplatin.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Yiquan Chen, Da Wang (2026). Identification of Drug-resistant Cell Subpopulations in Colorectal Cancer Through Single-cell Analysis and Exploration of Potential Therapeutic Strategies.. Current medicinal chemistry. https://doi.org/10.2174/0109298673490855260406093651
MLA Yiquan Chen, et al.. "Identification of Drug-resistant Cell Subpopulations in Colorectal Cancer Through Single-cell Analysis and Exploration of Potential Therapeutic Strategies.." Current medicinal chemistry, 2026.
PMID 42003098 ↗

Abstract

[INTRODUCTION] The therapeutic efficacy of Colorectal Cancer (CRC) is often compromised by resistance to the standard chemotherapy agent oxaliplatin.

[METHODS] This study obtained single-cell RNA sequencing (scRNA-seq) data from the Gene Expression Omnibus (GEO) database. Differentially Expressed Genes (DEGs) between resistant and sensitive epithelial subpopulations were identified, followed by enrichment analysis. Pseudotemporal trajectory and cell-cell communication were analyzed using Monocle2 and CellChat, respectively. The candidate drug was predicted by Connectivity Map (cMAP) analysis. External validation included assessment of the EpC2 signature in an oxaliplatin-resistant cell line dataset (GSE76092), survival analysis using The Cancer Genome Atlas (TCGA) cohorts, and re-analysis of the GSE179784 dataset to assess the reproducibility of EpC2-like subpopulations and their DNA Damage Repair (DDR) scores.

[RESULTS] Cell subpopulations were divided into 10 clusters. Among them, epithelial cells comprised 5 subpopulations, with EPC2 identified as a potential oxaliplatin-resistant subset. DEGs were enriched in the TNF and IL-17 pathways. External validation confirmed the enrichment of EpC2 in resistant cell lines and its association with poor survival. Pseudotemporal trajectory revealed that epithelial cells underwent state transitions, forming two distinct branches. The resistant group exhibited enrichment in RNA splicing and NF-κB pathways. Cell-cell communication analysis revealed interactions involving MDK- NCL and PPIA-BSG. Dasatinib was predicted as a candidate drug.

[DISCUSSION] We identified an oxaliplatin-resistant subpopulation of Epithelial Cells (EpC2) in CRC, elucidated its multi-layered resistance mechanisms, and integrated multi- omics and cMAP database analyses to predict a potential intervention drug.

[CONCLUSION] This study provided potential therapeutic possibilities for oxaliplatin resistance, contributing to CRC treatment.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반